Zaher Jabbour1, Michel El-Hakim2, Janet E Henderson3, Rubens F de Albuquerque4. 1. Division of Restorative Dentistry, Faculty of Dentistry, McGill University, Montreal, QC, Canada; Bone Engineering Labs, Research Institute, McGill University Health Center, Montreal, QC, Canada. 2. Division of Oral and Maxillofacial Surgery, Faculty of Dentistry, McGill University, Montreal, QC, Canada. 3. Bone Engineering Labs, Research Institute, McGill University Health Center, Montreal, QC, Canada; Department of Medicine and Surgery, Faculty of Medicine, McGill University, Montreal, QC, Canada. 4. Division of Restorative Dentistry, Faculty of Dentistry, McGill University, Montreal, QC, Canada; Department of Dental Materials and Prosthodontics, Faculty of Dentistry of Ribeirão Preto, University of Sao Paulo, Brazil. Electronic address: rubens.albuquerque@mcgill.ca.
Abstract
OBJECTIVE: This study aimed to evaluate the impact of concurrent administration of clinically relevant doses of zoledronic acid (ZA) and dexamethasone (DX) on bone healing after tooth extraction (EXO). MATERIALS AND METHODS: Forty-four Sprague-Dawley rats (6-8 month old) were randomized into five groups: ZA + DX = weekly injection of ZA with DX for 7 weeks; WD = ZA with DX for 3 weeks then DX alone for 4 weeks; C = control saline for 7 weeks; ZA = ZA alone for 7 weeks and DX = DX alone for 7 weeks. ZA was administered at 0.13 mg/kg/week and DX at 3.8 mg/kg/week and body weights recorded at the time of injection. All rats underwent extraction (EXO) of the mandibular and maxillary first molars at 3 weeks and were euthanized at 7 weeks. The extracted and non-extracted sides of both jaws were harvested for micro-CT analyses. RESULTS: All rats, particularly those injected with ZA, exhibited weight gain till EXO followed by decline then recovery. ZA + DX group demonstrated highest fractional bone to tissue volume (BV/TV) in the non-extracted side. ZA + DX rats exhibited also highest volume and surface of sequestra. Only sequestra volume was statistically higher in the WD group compared to C group. CONCLUSION: Combined treatment with ZA and DX over a prolonged period inhibits bone remodeling and increased sequestra formation to a greater extent than either drug alone. Trauma caused by these sequestra cutting through the mucosa could play a key role in the development of BRONJ by potentially facilitating infection. ZA withdrawal may promote bone-remodeling reactivation following EXO.
OBJECTIVE: This study aimed to evaluate the impact of concurrent administration of clinically relevant doses of zoledronic acid (ZA) and dexamethasone (DX) on bone healing after tooth extraction (EXO). MATERIALS AND METHODS: Forty-four Sprague-Dawley rats (6-8 month old) were randomized into five groups: ZA + DX = weekly injection of ZA with DX for 7 weeks; WD = ZA with DX for 3 weeks then DX alone for 4 weeks; C = control saline for 7 weeks; ZA = ZA alone for 7 weeks and DX = DX alone for 7 weeks. ZA was administered at 0.13 mg/kg/week and DX at 3.8 mg/kg/week and body weights recorded at the time of injection. All rats underwent extraction (EXO) of the mandibular and maxillary first molars at 3 weeks and were euthanized at 7 weeks. The extracted and non-extracted sides of both jaws were harvested for micro-CT analyses. RESULTS: All rats, particularly those injected with ZA, exhibited weight gain till EXO followed by decline then recovery. ZA + DX group demonstrated highest fractional bone to tissue volume (BV/TV) in the non-extracted side. ZA + DXrats exhibited also highest volume and surface of sequestra. Only sequestra volume was statistically higher in the WD group compared to C group. CONCLUSION: Combined treatment with ZA and DX over a prolonged period inhibits bone remodeling and increased sequestra formation to a greater extent than either drug alone. Trauma caused by these sequestra cutting through the mucosa could play a key role in the development of BRONJ by potentially facilitating infection. ZA withdrawal may promote bone-remodeling reactivation following EXO.
Authors: Giovanni Mergoni; Paolo Vescovi; Roberto Sala; Elisabetta Merigo; Pietro Passerini; Roberta Maestri; Domenico Corradi; Paolo Govoni; Samir Nammour; Massimiliano G Bianchi Journal: Support Care Cancer Date: 2015-07-21 Impact factor: 3.603
Authors: Vivian Bradaschia-Correa; Giovanna C Ribeiro-Santos; Lorraine Perciliano de Faria; Paula Rezende-Teixeira; Victor E Arana-Chavez Journal: J Mol Histol Date: 2022-06-14 Impact factor: 3.156
Authors: R Nicole Howie; James L Borke; Zoya Kurago; Asma Daoudi; James Cray; Ibrahim E Zakhary; Tara L Brown; J Nathan Raley; Loan T Tran; Regina Messer; Fardous Medani; Mohammed E Elsalanty Journal: PLoS One Date: 2015-07-17 Impact factor: 3.240
Authors: Rodolfo Mauceri; Vera Panzarella; Laura Maniscalco; Alberto Bedogni; Maria Ester Licata; Antonino Albanese; Francesca Toia; Enzo Maria Giuseppe Cumbo; Giuseppina Mazzola; Olga Di Fede; Giuseppina Campisi Journal: Biomed Res Int Date: 2018-08-19 Impact factor: 3.411
Authors: Jing Yi Wang; Lei Huo; Ru Qing Yu; Nian Jing Rao; Weijia William Lu; Li Wu Zheng Journal: Biomed Res Int Date: 2019-12-18 Impact factor: 3.411
Authors: Megan E Cooke; Jose L Ramirez-GarciaLuna; Karla Rangel-Berridi; Hyeree Park; Showan N Nazhat; Michael H Weber; Janet E Henderson; Derek H Rosenzweig Journal: Front Bioeng Biotechnol Date: 2020-10-23